Brief: Algernon Pharmaceuticals Inc Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
08/10/2021 12:07
Oct 8 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS FILES U.S. FDA PRE-IND MEETING
REQUEST
FOR IFENPRODIL CHRONIC COUGH PHASE 2 STUDY
Source text for Eikon: ID:nGNX6tPv15
Further company coverage: AGN.CD
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement